Condition
Von Willebrand Disease, Type 3
Total Trials
4
Recruiting
3
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 3 (1)
Trial Status
Recruiting3
Enrolling By Invitation1
Clinical Trials (4)
Showing 4 of 4 trials
NCT06998524Phase 3RecruitingPrimary
A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease
NCT06883240RecruitingPrimary
An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment
NCT05500807Phase 1RecruitingPrimary
Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A
NCT03655223Enrolling By Invitation
Early Check: Expanded Screening in Newborns
Showing all 4 trials